Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs located in Germany, and U-Medico, an innovative formulation development and biophysical characterizations service provider located in Japan, have formed an alliance that includes an equity investment by Coriolis Pharma into U-Medico.

The alliance aims to extend Coriolis Pharma’s expertise, service portfolio and market reach into the Japanese and Asian market, while strengthening U-Medico’s formulation development and biophysical characterization services, as well as expertise by giving integrated access to Coriolis Pharma’s service portfolio. Together, Coriolis Pharma and U-Medico will work on development projects for clients and enable innovative therapies by revolutionizing formulation development and biophysical characterizations of biopharmaceuticals and ATMPs, such as viral vectors and gene- and cell therapies for clients worldwide.

In addition, researchers from both companies will exchange scientific knowledge and work together in scientific collaborations, to generate know-how and publications in the field of formulation development and characterization of biopharmaceuticals and gene- and cell therapy products.

“U-medico is the leading provider of science-driven formulation development and biophysical characterization services in Japan and we as Coriolis are proud to become part of it,” said Dr. Michael Wiggenhorn, CEO, Coriolis Pharma. “The strategic alliance is the next step for Coriolis Pharma growths strategy based on excellent science.”

Prof. Dr. Susumu Uchiyama, founder and chief scientific officer of U-Medico, already joined the scientific advisory board of Coriolis Pharma in September 2021. Prof. Uchiyama is also leading the Japanse national project consortium for the development of characterization and quality control of virus vectors for gene therapy.

Dr. Ayano Fukuhara, CEO, U-Medico, said, “This strategic alliance strengthens the scientific collaboration between Coriolis and U-Medico. We are excited to grow together and support our clients with more specialized and high-quality formulation development services.”

Prof. Uchiyama concluded, “In-depth biophysical chemistry knowledge based on high-quality science is essential for the characterizations of biopharmaceuticals and virus vectors. This alliance will definitely contribute to the development of biopharmaceuticals and ATMPs with high quality and safety.”